FilingsTodayModerna
At a glance
Moderna reported 2025 revenue of $1.94B, down 39.9% from $3.24B in 2024. Over 4 years since 2021 ($18.47B), that is a decline of about 43% a year. Operating margin was -158.1%, down from 72% in 2021. Revenue peaked in 2022 at $19.26B. The company posted a loss in 2023, 2024 and 2025.
In the last 12 months 6 insiders reported 0 open-market purchases and 15 sales ($81.6M). 13 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $28.7M by Chief Executive Officer Stephane Bancel on Aug 7, 2026.
Moderna filed 15 current reports (Form 8-K) in the last 12 months, most often for results of operations (5), material agreement (3), regulation fd disclosure (3) and officer or director change (2). The latest officer or director change was reported on Sep 30, 2026. It reported a material agreement or a completed acquisition or disposal 3 times.
1 of the 20 investors tracked here held Moderna at the last quarter end, worth $807K combined. It is the largest weight for Bridgewater Associates (0% of its portfolio). Reduced: Bridgewater Associates.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | $12.2B | $8.36B | -$4.71B | -$3.56B | -$2.82B |
| Diluted EPS | $28.29 | $20.12 | $-12.33 | $-9.28 | $-7.26 |
Fiscal year ends Dec 31 · incorporated in DE
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined